Safe Supply Streaming Co. Ltd. entered into a binding letter of intent to acquire Origin Therapeutics Holdings Inc. (CNSX:ORIG) in a reverse merger transaction on January 23, 2023. Safe Supply Streaming Co. Ltd. entered into a definitive agreement to acquire Origin Therapeutics Holdings Inc. in a reverse merger transaction on August 1, 2023. Pursuant to the transaction, all outstanding securities of Safe Supply will be exchanged by the holders thereof for identical securities of the Resulting Issuer on a post-Consolidation one-for-one basis. Post-acquisition, the board of directors of the Resulting Issuer shall be reconstituted to consist of such directors as Safe Supply and the Company shall determine, and certain officers of the Company shall resign and be replaced with officers appointed by the new board of directors.

The completion of the transaction is subject to a number of conditions, including, among other items: (i) the entering into of the definitive agreement by no later than March 31, 2023, (ii) the consolidation of the Origin?s existing share capital on a 4-for-1 basis or such other basis, (iii) Origin changing its name to ?Safe Supply Streaming Co Ltd.? or such other mutually determined name, (iv) completion of the Private Placement, (v) the entering into by Safe Supply of certain letters of intent with respect to streaming opportunities, (vi) receipt of all required shareholder, regulatory and third party consents, including approval of the transaction by the Canadian Securities Exchange, and (vii) the listing of the shares of the Resulting Issuer on the CSE. On September 11, 2023 Safe Supply Streaming and Origin Therapeutics have received conditional approval to list Safe Supply?s common shares on the Canadian Securities Exchange. Final approval and trading of the Company shares are subject to fulfilling customary CSE requirements. The parties intend to enter into a definitive agreement by no later than February 28, 2023, or such other date as may be agreed to by Safe Supply and Origin. The transaction is expected to close in early spring 2023. Subject to certain closing conditions, the Transaction is expected to close in early September 2023. Jeff Hergott of Wildeboer Dellelce LLP acted as legal advisor for Origin. Aaron Sonshine and Corey Yermus of Bennett Jones LLP acted as legal advisor for Safe Supply, Hyperion Capital Inc. acted as financial advisor and provided fairness opinion to Origin Therapeutics Holdings